RNAi is among the newer approaches providing higher specificity. Companies having a rich RNAi portfolio have their proprietary platforms and have been clear in targeting difficult to treat diseases. In August, the EASL (27 – 29 Aug) and ESC (29 Aug – 01 Sep) congresses show cased important progress by the RNAi players. The large investments and collaborations in this field points to the promise and belief in this treatment approach. As we look at NASH, HBV, RCC, CF – its heartening to see the positive signals from early trials. In this digest we are covering: Alnylam, Arbutus, Dicerna, Arrowhead pharmaceuticals, Novartis and Janssen.